BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 9085735)

  • 21. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
    Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progenitor cell numbers (CFU-GM, CFU-D, and CFU-Mix) and hemopoietic recovery following autologous marrow transplantation.
    Stewart FM; Kaiser DL; Ishitani KP; Pirsch GW; Niskanen E
    Exp Hematol; 1989 Oct; 17(9):974-80. PubMed ID: 2673831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants.
    To LB; Roberts MM; Haylock DN; Dyson PG; Branford AL; Thorp D; Ho JQ; Dart GW; Horvath N; Davy ML
    Bone Marrow Transplant; 1992 Apr; 9(4):277-84. PubMed ID: 1350938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A comparative study of unrelated donor bone marrow transplantation and peripheral blood stem cell transplantation for their therapeutic effects on leukemia].
    Fan ZP; Yang K; Liu QF; Sun J; Xu D; Zhang Y; Wei YQ; Ye CX; Jiang QL; Meng FY
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Oct; 26(10):1494-7, 1512. PubMed ID: 17062361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of T-, B- and NK-cell reconstitution following conventional or nonmyeloablative conditioning and transplantation with bone marrow or peripheral blood stem cells from human leucocyte antigen identical sibling donors.
    Petersen SL; Ryder LP; Björk P; Madsen HO; Heilmann C; Jacobsen N; Sengeløv H; Vindeløv LL
    Bone Marrow Transplant; 2003 Jul; 32(1):65-72. PubMed ID: 12815480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma.
    Martín A; Pérez-Simón JA; Caballero MD; López-Holgado N; Vázquez L; del Cañizo MC; San Miguel JF
    Haematologica; 2005 Jan; 90(1):78-85. PubMed ID: 15642673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The importance of CD34+/CD33- cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue.
    Millar BC; Millar JL; Shepherd V; Blackwell P; Porter H; Cunningham D; Judson I; Treleaven J; Powles RL; Catovsky D
    Bone Marrow Transplant; 1998 Sep; 22(5):469-75. PubMed ID: 9733270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen.
    Dey BR; Shaffer J; Yee AJ; McAfee S; Caron M; Power K; Ting DT; Colby C; Preffer F; Ballen K; Attar E; Saidman S; Tarbell N; Sachs D; Sykes M; Spitzer TR
    Bone Marrow Transplant; 2007 Jul; 40(1):19-27. PubMed ID: 17468773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disease- or therapy-related bone marrow damage cannot be overcome by changes in stem cell source or dose in allogeneic transplantation.
    Novotny JR; Rosenthal C; Elmaagacli AH; Dürig J; Beelen DW; Dührsen U
    Eur J Haematol; 2004 Jul; 73(1):1-9. PubMed ID: 15182331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients.
    Kasow KA; Sims-Poston L; Eldridge P; Hale GA
    Biol Blood Marrow Transplant; 2007 May; 13(5):608-14. PubMed ID: 17448921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors predicting morbidity following hematopoietic stem cell transplantation.
    Gordon B; Haire W; Ruby E; Kotulak G; Stephens L; Kessinger A; Armitage J
    Bone Marrow Transplant; 1997 Mar; 19(5):497-501. PubMed ID: 9052918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors affecting recovery after peripheral blood stem cell transplantation.
    Morse EE; Tuck D; Ascensao J; Sorba S; Dainiak N
    Ann Clin Lab Sci; 1993; 23(2):89-96. PubMed ID: 7681274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
    Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR
    Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune reconstitution after purified autologous and allogeneic blood stem cell transplantation compared with unmanipulated bone marrow transplantation in children.
    Schwinger W; Weber-Mzell D; Zois B; Rojacher T; Benesch M; Lackner H; Dornbusch HJ; Sovinz P; Moser A; Lanzer G; Schauenstein K; Ofner P; Handgretinger R; Urban C
    Br J Haematol; 2006 Oct; 135(1):76-84. PubMed ID: 16925797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies.
    Carral A; de la Rubia J; Martín G; Martínez J; Sanz G; Jarque I; Sempere A; Soler MA; Marty ML; Sanz MA
    Bone Marrow Transplant; 2002 May; 29(10):825-32. PubMed ID: 12058232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K; Margolin K; Champlin R; Forman S
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
    Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term cryopreservation of bone marrow for autologous transplantation.
    Attarian H; Feng Z; Buckner CD; MacLeod B; Rowley SD
    Bone Marrow Transplant; 1996 Mar; 17(3):425-30. PubMed ID: 8704699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.